Brokerages forecast that Boston Scientific Corporation (NYSE:BSX) will report sales of $2.20 billion for the current fiscal quarter, according to Zacks Investment Research. Ten analysts have provided estimates for Boston Scientific Corporation’s earnings. The lowest sales estimate is $2.19 billion and the highest is $2.21 billion. Boston Scientific Corporation reported sales of $2.11 billion during the same quarter last year, which would suggest a positive year-over-year growth rate of 4.3%. The firm is expected to issue its next quarterly earnings results on Wednesday, October 25th.

According to Zacks, analysts expect that Boston Scientific Corporation will report full year sales of $2.20 billion for the current year, with estimates ranging from $8.91 billion to $9.01 billion. For the next financial year, analysts expect that the business will report sales of $9.58 billion per share, with estimates ranging from $9.47 billion to $9.70 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that follow Boston Scientific Corporation.

Boston Scientific Corporation (NYSE:BSX) last posted its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.01. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. The company had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.21 billion. During the same period last year, the firm earned $0.27 earnings per share. Boston Scientific Corporation’s quarterly revenue was up 6.2% on a year-over-year basis.

BSX has been the topic of several research analyst reports. Jefferies Group LLC reaffirmed a “hold” rating on shares of Boston Scientific Corporation in a research report on Thursday, September 7th. Royal Bank Of Canada reaffirmed a “buy” rating and set a $31.00 price target on shares of Boston Scientific Corporation in a research report on Friday, September 1st. BidaskClub cut shares of Boston Scientific Corporation from a “hold” rating to a “sell” rating in a research report on Saturday, August 26th. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Boston Scientific Corporation in a research report on Wednesday, August 9th. Finally, UBS AG reaffirmed a “buy” rating and set a $31.00 price target (up previously from $30.00) on shares of Boston Scientific Corporation in a research report on Tuesday, August 1st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. Boston Scientific Corporation currently has an average rating of “Buy” and a consensus price target of $29.88.

WARNING: This piece was originally reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/09/24/boston-scientific-corporation-bsx-expected-to-announce-quarterly-sales-of-2-20-billion.html.

In other Boston Scientific Corporation news, EVP Timothy A. Pratt sold 10,104 shares of the stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $27.46, for a total value of $277,455.84. Following the completion of the sale, the executive vice president now owns 185,742 shares in the company, valued at approximately $5,100,475.32. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Maulik Nanavaty sold 27,031 shares of the stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $27.08, for a total transaction of $731,999.48. The disclosure for this sale can be found here. In the last quarter, insiders sold 275,257 shares of company stock valued at $7,512,394. Insiders own 0.74% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. Lord Abbett & CO. LLC bought a new position in shares of Boston Scientific Corporation during the 2nd quarter valued at $40,460,000. Sentry Investment Management LLC raised its holdings in shares of Boston Scientific Corporation by 1.1% during the 2nd quarter. Sentry Investment Management LLC now owns 107,243 shares of the medical equipment provider’s stock valued at $2,973,000 after purchasing an additional 1,125 shares in the last quarter. WFG Advisors LP raised its holdings in shares of Boston Scientific Corporation by 17.3% during the 2nd quarter. WFG Advisors LP now owns 157,919 shares of the medical equipment provider’s stock valued at $4,378,000 after purchasing an additional 23,305 shares in the last quarter. Toronto Dominion Bank raised its holdings in shares of Boston Scientific Corporation by 26.1% during the 2nd quarter. Toronto Dominion Bank now owns 463,826 shares of the medical equipment provider’s stock valued at $12,854,000 after purchasing an additional 95,902 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd raised its holdings in shares of Boston Scientific Corporation by 80.8% during the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 16,800 shares of the medical equipment provider’s stock valued at $466,000 after purchasing an additional 7,507 shares in the last quarter. Institutional investors and hedge funds own 90.44% of the company’s stock.

Boston Scientific Corporation (NYSE:BSX) traded up 0.31% during mid-day trading on Thursday, reaching $28.85. The company’s stock had a trading volume of 3,131,553 shares. The stock’s 50 day moving average price is $27.39 and its 200 day moving average price is $26.61. The stock has a market capitalization of $39.59 billion, a P/E ratio of 51.61 and a beta of 1.09. Boston Scientific Corporation has a 1-year low of $19.67 and a 1-year high of $29.40.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Get a free copy of the Zacks research report on Boston Scientific Corporation (BSX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.